Bausch Health Companies Inc. Stock Toronto S.E.

Equities

BHC

CA0717341071

Pharmaceuticals

Delayed Toronto S.E. 16:00:00 2024-07-16 EDT 5-day change 1st Jan Change
10.32 CAD +2.89% Intraday chart for Bausch Health Companies Inc. +5.20% -2.92%
Sales 2024 * 9.4B 12.85B Sales 2025 * 9.69B 13.24B Capitalization 2.77B 3.79B
Net income 2024 * 144M 197M Net income 2025 * 386M 528M EV / Sales 2024 * 2.47 x
Net Debt 2024 * 20.44B 27.94B Net Debt 2025 * 19.09B 26.09B EV / Sales 2025 * 2.26 x
P/E ratio 2024 *
23.1 x
P/E ratio 2025 *
7.21 x
Employees 20,270
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.53%
More Fundamentals * Assessed data
Dynamic Chart
Raymond James Initiates Bausch Health at Market Perform Rating MT
Bausch Health Sues Norwich for Patent Infringement Over Application for Generic Version of IBS Drug MT
Bausch + Lomb Brief: To Present New Data at European Dry Eye Society 2024 Congress; Events Include Symposium on Patient-Centric Approaches to Dry Eye, "Highlighting Breakthroughs in Diagnosis, Treatment and Care" MT
Bausch + Lomb Brief: Launching "Clinically Proven" Nutritional Supplement for Dry Eyes in the United States MT
Bausch + Lomb Brief: Says Received Health Canada Approval for Full Visual Range Intraocular Lens MT
Bausch Health Announces Wider Public Drug Plan Coverage for Uceris in Canada MT
Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024 CI
RBC Notes Updates on Bausch Xifaxan Patent Litigation with Norwich MT
Bausch Health Companies Inc. Approves Directorate Appointments CI
Bausch Health Down 6.6% In US After Hours As Updates Related to Norwich XIFAXAN Matters MT
Bausch Health Brief: Announcing Updates Related to Norwich XIFAXAN Matters MT
RBC Noes Bausch Health Filing For Rehearing in Appellate Court MT
RBC Lowers Bausch Health Target to US$10, Maintains Sector Perform MT
Bausch Health Shares Fall Following Q1 Results MT
Bausch Health Q1 Net Loss Narrows on Higher Revenue, Confirms 2024 Revenue Guidance MT
More news
1 day+2.89%
1 week+5.20%
Current month+8.18%
1 month+19.03%
3 months-14.50%
6 months-9.15%
Current year-2.92%
More quotes
1 week
9.93
Extreme 9.925
10.47
1 month
8.62
Extreme 8.615
10.47
Current year
8.32
Extreme 8.32
15.43
1 year
8.32
Extreme 8.32
15.43
3 years
5.10
Extreme 5.1
37.42
5 years
5.10
Extreme 5.1
43.97
10 years
5.10
Extreme 5.1
347.84
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 -
Director of Finance/CFO 51 22-05-23
Chief Operating Officer - -
Members of the board TitleAgeSince
Director/Board Member 67 08-07-31
Chairman 68 17-05-31
Director/Board Member 35 21-03-16
More insiders
Date Price Change Volume
24-07-16 10.32 +2.89% 438,365
24-07-15 10.03 -0.69% 430,540
24-07-12 10.1 -1.85% 425,005
24-07-11 10.29 +3.11% 335,564
24-07-10 9.98 +1.73% 431,597

Delayed Quote Toronto S.E., July 16, 2024 at 04:00 pm

More quotes
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
7.55 USD
Average target price
9.562 USD
Spread / Average Target
+26.66%
Consensus